The history of (and perhaps the lessons to be learned from) peritoneal CA125 investigation presents no better example of the diffi culties in assigning the status of a 'marker' predictive of membrane dysfunction to factors measured in dialysis effl uent. In 1995, Visser et al. [3] were the fi rst to suggest that CA125 could be used as 'a bulk marker of mesothelial cell mass in stable PD patients'. This was suggested based largely on in vitro and ex vivo approaches that suggested a mesothelial-cell-specifi c location (i.e. it is not expressed by leucocytes). Their data also suggested passive secretion of the antigen and a relationship to the number of mesothelial cells in culture. These data on the 'regulation' of secretion, however, were at odds with both pre-existing and subsequently produced data suggestive of induction of CA125 by pro-infl ammatory cytokines [4, 5] . In the current issue, Br e ˛ borowicz et al. fan the fl ames of this debate further by suggesting, based exclusively on in vitro data, that CA125 production by peritoneal mesothelial cells neither correlates with, nor is regulated by pro-infl ammatory cytokines [6] .
The evidence ascribing CA125 as a clinical marker of mesothelial cell or membrane integrity was apparently strengthened by the studies of Ho-dac Panekeet et al. [7] who presented cross-sectional data suggesting a relationIdentifying easily measurable markers that are of prognostic value in predicting membrane failure in peritoneal dialysis (PD) patients remains one of the major challenges. Facilitating this endeavour has always been the ease of sampling of drained peritoneal effl uent within which, with the development of ever more sensitive measurement techniques, any number of mediators can be quantitated. Local production of these 'factors' (i.e. of peritoneal membrane or infi ltrating leucocyte origin) would then theoretically, at least, allow changes to be correlated with clinical outcomes and thereby their usefulness as indicators of altered membrane status. So far then there is an attractiveness and inescapable logic to this type of approach that would predict that after almost 20 years of investigation (since the fi rst measurements of prostaglandins in peritoneal effl uent [1, 2] ) there would now be suffi cient data on a number of markers predictive of clinical and membrane-associated changes in these patients. Unfortunately, however, despite signifi cant scientifi c endeavour (and as we will discuss a number of long-term clinical studies) we are really little nearer to identifying our holy grail. ship between effl uent CA125 levels and the time spent on PD. Again these data were highly contentious as Lai et al. [8] were unable to reproduce it in a study of similar size. At face value these apparently disparate fi ndings would seem to cast serious doubt on the validity of CA125 as a marker of mesothelial cell mass or membrane integrity.
More recently, however, evidence for a benefi cial relationship between CA125 levels and peritoneal 'health' has been reinforced based largely on studies comparing dialysis solution biocompatibility in short-to mediumterm randomised controlled clinical trials. In summary, continuous exposure of patients to solutions manufactured to be more biocompatible (e.g. neutral or physiological pH and reduced glucose degradation product levels) resulted in each of the studies in signifi cant elevation of CA125 effl uent levels that have been ascribed as evidence of increased mesothelial cell and membrane integrity [9] [10] [11] . Interestingly and yet unexplained, however, are the large differences in the magnitude of these changes in CA125 when comparing the different solutions in similar patient populations.
Clearly, there are a number of major diffi culties with the 'CA125 hypothesis'. Principal among these is the fact that despite a signifi cant and relatively recent increase in our understanding of its biology (see below), there are still far more questions than answers about what CA125 is doing in the peritoneal cavity and how its expression (both surface expression and secretion) are regulated. Data produced largely over the past few years allow us to answer the fi rst part of this question, to partly answer the second but unfortunately data relating to its function remain far less clear. Historically, CA125 was identifi ed as an antigen reacting to the OC125 antibody in 1981 by Bast et al. [12] and is used clinically as the gold standard for monitoring ovarian neoplasms. Despite this its structure and function have remained largely unstudied until recently. The groups of O'Brien and Lloyd have produced much of the data relating to its molecular and genetic structure in the last few years [13] [14] [15] . It is now recognised that the CA125 molecule is a truly massive transmembrane glycoprotein consisting of multiple (60+) repeat domains and an amino terminus. The extracellular portion is highly glycosylated [13] .
The regulation of expression of such a vast extracellular structure is likely to be complex, while extensive work has shed little light on how its secretion is controlled. The most recent mRNA sequence available for CA125 (AF414442) exceeds 66 kb and resolves to 84 exons spanning over 130 kb of genomic DNA. This vast message encodes a theoretical product of 22,152 amino acids, although due to the highly iterative nature of the repeat region both nucleotide and translated amino acid sequences contain signifi cant numbers of unknown residues.
The CA125 mRNA was fi rst characterised as a 5.8-kb transcript [16] before 5 additions extended the sequence to its present form [13, 14] . Mindful of these successive recent expansions, we have analysed CA125 mRNA isolated from human peritoneal mesothelial cells using the 5 rapid amplifi cation of cDNA end technology described recently in the identifi cation of the transcription start site of the hyaluronan synthase 2 gene [17] . Our preliminary data have extended the CA125 sequence but suggest that further major additions are unlikely. How CA125 production is regulated at the mRNA level is unknown, and we are currently analysing the relevant upstream putative promoter sequences to identify elements involved in the regulation of its transcription [Michael et al., unpubl. data].
How CA125 is secreted is likewise still unclear, although its intracellular domain structure is suggestive of some signalling capacity, its size and the presence of a putative cleavage site suggest that proteolytic cleavage of the extracellular domains is the most likely scenario by which it is released. To date, however, neither the cleavage site, the size(s) of the released fragments, nor the enzyme(s) responsible for this have been identifi ed [13] .
CA125: Where Are We Now?
Therein lies the rub, whilst we know what it is, what it looks like and which cells express it, we have little idea of its biological signifi cance. Although it is related genetically to the mucin (MUC) family (and in fact may indeed be encoded by the MUCIN 16 gene [15] ), suggestive of a putative role in peritoneal lubrication, there is no clear evidence for this function.
One also has to ask the question whether comparing CA125 data based on in vitro and in vivo studies is really equivalent? If one does a simple calculation of appearance rates comparing published rates in patients (which are remarkably similar between studies) with those of Br e ˛ borowicz et al. [6] and other in vitro studies, then the rate of production in vitro is some 10-30 times higher. Whilst measurements in different matrices (tissue culture medium vs. effl uent) might explain a small difference, there are clearly differences between a clean in vitro setup and the uremic peritoneal cavity exposed to both glucose-based dialysis solutions and intercurrent or episodic infl ammation. Interestingly. Br e ˛ borowicz et al. [6] do show that chronic exposure of mesothelial cells to glucose specifi cally reduces mesothelial cell CA125 secretion and expression. Since glucose is the major osmotic agent used in PD fl uids, this may in part help us to understand why its production in vivo is suppressed and that more biocompatible solutions increase its levels [9] [10] [11] . Given that more biocompatible solutions also contain equal amounts of glucose, however, the relationship to CA125 regulation is once again far from straightforward.
Conclusions and Future Perspectives
The debate will no doubt run and run, however until we properly defi ne the regulation of CA125 at the molecular level, how and what controls its secretion/shedding and most importantly its biological signifi cance/role, we will continue to be somewhat in the dark. The recent identifi cation of its genetic structure provides a glimmer of hope as it now allows more defi ned studies on its molecular regulation and expression to be planned. Although not currently available, this information will likely pave the way for the generation of a CA125-defi cient mouse (if viable) and the capacity to 'knock-down' its expression. Both of these approaches would doubtlessly provide benefi t in understanding CA125 biology. With respect to its pre-eminent place as a marker of membrane integrity in PD, the data are still far from convincing and certainly continue to polarise opinion. If CA125 is to be that holy grail that we seek then we will need to marry in vitro investigation of CA125 regulation with studies to defi ne longitudinal changes in large cohorts of PD patients and controls. Once enough data are collected we will be able to analyse those clinical factors that impact on its production in the peritoneal cavity. If we fail to do this, CA125 will remain the enigma that it currently is and the search for the illusive marker of peritoneal membrane survival will go on and on.
